A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Taiho Oncology, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Arcus Biosciences, Inc.
Seagen Inc.
University of Rochester
University Hospital Schleswig-Holstein